Open4.680 | Close- |
Vol / Avg.1.438M / 1.618M | Mkt Cap1.373B |
Day Range4.530 - 4.850 | 52 Wk Range3.870 - 13.990 |
AbCellera Biologics Stock (NASDAQ: ABCL) stock price, news, charts, stock research, profile.
Open4.680 | Close- |
Vol / Avg.1.438M / 1.618M | Mkt Cap1.373B |
Day Range4.530 - 4.850 | 52 Wk Range3.870 - 13.990 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.130 | -0.100 | 0.0300 | ||||
REV | 11.900M | 6.599M | -5.301M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-10-13 | Piper Sandler | Allison Bratzel | Assumes | Overweight | Announces | - | 20.00 |
2023-08-31 | Benchmark | Robert Wasserman | Maintains | BuyBuy | Lowers | 20.00 | 12.00 |
2023-08-04 | Goldman Sachs | Andrea Tan | Maintains | BuyBuy | Lowers | 27.00 | 24.00 |
2023-05-05 | Credit Suisse | Tiago Fauth | Maintains | Outperform | Lowers | 34.00 | 28.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ABCL | AbCellera Biologics | 1.17% | 1.4B |
MEDP | Medpace Hldgs | 1% | 8.4B |
A | Agilent Technologies | 0.42% | 37.6B |
TXG | 10x Genomics | 3.24% | 5.3B |
WAT | Waters | 2.12% | 16.9B |
You can purchase shares of AbCellera Biologics (NASDAQ: ABCL) through any online brokerage.
Other companies in AbCellera Biologics’s space includes: Medpace Hldgs (NASDAQ:MEDP), Agilent Technologies (NYSE:A), 10x Genomics (NASDAQ:TXG), Waters (NYSE:WAT) and Danaher (NYSE:DHR).
The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Piper Sandler on Friday, October 13, 2023. The analyst firm set a price target for 20.00 expecting ABCL to rise to within 12 months (a possible 319.73% upside). 9 analyst firms have reported ratings in the last year.
The stock price for AbCellera Biologics (NASDAQ: ABCL) is $4.765 last updated Today at December 1, 2023 at 7:48 PM UTC.
There is no dividend information for AbCellera Biologics.
AbCellera Biologics’s Q4 earnings are confirmed for Tuesday, February 20, 2024.
There is no upcoming split for AbCellera Biologics.
AbCellera Biologics is in the Health Care sector and Life Sciences Tools & Services industry. They are listed on the NASDAQ.